scholarly journals Is post‐transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?

2020 ◽  
Vol 40 (9) ◽  
pp. 461-464
Author(s):  
Giovanni Brandi ◽  
Angela Dalia Ricci ◽  
Alessandro Rizzo ◽  
Chiara Zanfi ◽  
Simona Tavolari ◽  
...  
2015 ◽  
Vol 262 (1) ◽  
pp. e12 ◽  
Author(s):  
Paulo Ney Aguiar Martins ◽  
Babak Movahedi ◽  
Adel Bozorgzadeh

2020 ◽  
pp. 1-6
Author(s):  
Zhiming Zhao ◽  
Mengyang Li ◽  
Xianglong Tan ◽  
Zhiming Zhao

The liver is the most common site of metastasis in colorectal cancer (CRC). Treatment of liver metastases determines the prognosis of patients with CRC. Tremendous progress has been made during the last two decades, which has greatly improved the overall survival of CRC patients. Currently, various treatment options are available, including hepatectomy, liver transplantation, local regional therapy, chemotherapy, targeted therapy, and immune therapy, inevitably leading to some controversies on treatment indications and selection of treatment strategy. Here, we reviewed the existing approaches to treat colorectal cancer liver metastases, with the aim of examining several crucial questions regarding surgical resection, liver transplantation, and medical treatment in clinical practice.


2020 ◽  
Vol 04 (01) ◽  
pp. 013-018
Author(s):  
Koji Tomiyama ◽  
M. Katherine Dokus ◽  
Jennie Errigo ◽  
Marie Laryea ◽  
Roberto Hernandez-Alejandro

AbstractAs chemotherapy for colorectal cancer becomes effective for extending long-term survival, its liver metastases (colorectal cancer liver metastases [CRCLM]) are considered as the progression that best defines patient survival. Surgical resection is the most effective and only curative treatment for CRCLM. Although advancement in liver surgery to increase resectability of CRCLM has borne fruit, there are still limitations, namely tumor burden, remnant liver volume, and chemotherapy-related liver damage. CRCLM used to be considered a contraindication for liver transplantation (LTx) based on preliminary experience in the early era of LTx. Recent advancement in chemotherapy and surgical resection for CRCLM as well as improved outcome of LTx have attracted interest in revisiting this old dogma of LTx for CRCLM. Preliminary experience from Norway has shown promising results and potential for long-term survival with LTx. In this article, we review the history of LTx for CRCLM, rationale for revisiting the concept, early experience from Norway and discuss the issues around and future perspectives on LTx for CRCLM.


Sign in / Sign up

Export Citation Format

Share Document